Please login to the form below
Heron Therapeutics
This page shows the latest Heron Therapeutics news and features for those working in and with pharma, biotech and healthcare.
FDA awards another non-opioid pain drug breakthrough status
Concentric specialises in novel non-opioid pain therapeutics, and CA-008 is a first-in-class non-opioid therapeutic that rapidly converts to capsaicin, a potent TRPV1-agonist. ... The announcement follows a BTD in June for Heron Therapeutics and its
Latest news
-
Heron boosted by new data for ‘breakthrough’ pain drug
for postoperative pain management, in phase III studies,” said Barry Quart, Heron’s chief executive. ... March that Exparel sales would fall off dramatically if HTX-011 is approved – particularly as she thinks Heron’s drug is likely to be cheaper.
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval
- EU outlines measures to mitigate antibiotic shortage across Europe
- Europe’s cancer community publishes new report on transforming patient care
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Takeda’s all-oral multiple myeloma triplet therapy recommended by NICE
- Why everyone in pharma is bending over backwards to be agile
- Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval
PMHub
KVA
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
